immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Immunocore Ltd., part of Immunocore Holdings Plc, is a company headquartered in Oxon, UK. The firm develops and commercializes transformative medicines for cancer, infection and autoimmune disease. It was founded in 2007. Bahija Jallal is the current CEO of the firm.\nThe company says this about itself: Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

Xiangxue Life Science Technology (Guangdong) Co., Ltd., established on 2020-12-23, Business scope includes general items:R&D and application of cell technology;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Drug import and export;pharmaceutical production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.

Medigene Immunotherapies GmbH, part of MediGene AG, is a company headquartered in Planegg, Germany. The firm develops immunotherapy to treat cancer. It was founded in 2013 by Thomas Blankenstein and Dolores J. Schendel. Axel-Sven Malkomes is currently the CEO of the company. Medigene Immunotherapies GmbH was acquired by MediGene AG on January 27, 2014 for $13.05 million.\nThe company says this about itself: Based on more than 15 years of extensive research in the field of immunotherapy, Medigene Immunotherapies GmbH (formerly Trianta Immunotherapies GmbH) was founded late 2013 as a spin-off of the Helmholtz Zentrum München and was acquired by Medigene as a 100%subsidiary in January 2014. Medigene Immunotherapies pursues three complementary immunotherapeutic strategies to target various tumour types and stages: next generation antigen-tailored dendritic cell (DC)vaccines, T cell receptor (TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is focused on T cells, a type of white blood cell that plays a pivotal role in immunity.

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.